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Abstract
Background: Prospective meta-analysis (PMA) is a collaborative research design in which individual sites
perform randomized controlled trials (RCTs) and pool the data for meta-analysis. Members of the PMA
collaboration agree upon specific research interventions and outcome measures, ideally before initiation but at
least prior to any individual trial publishing results. This allows for uniform reporting of primary and secondary
outcomes. With this approach, heterogeneity among trials contributing data for the final meta-analysis is
minimized while each site maintains the freedom to design a specific trial. This paper describes the process of
creating a PMA collaboration to evaluate the impact of misoprostol on ease of intrauterine device (IUD)
insertion in nulliparous women.
Methods: After the principal investigator developed a preliminary PMA protocol, he identified potential
collaborating investigators at other sites. One site already had a trial underway and another site was in the
planning stages of a trial meeting PMA requirements. Investigators at six sites joined the PMA collaborative. Each
site committed to enroll subjects to meet a pre-determined total sample size. A final common research plan and
site responsibilities were developed and agreed upon through email and face-to-face meetings. Each site
committed to contribute individual patient data to the PMA collaboration, and these data will be analyzed and
prepared as a multi-site publication. Individual sites retain the ability to analyze and publish their site’s independent
findings.
Results: All six sites have obtained Institutional Review Board approval and each has obtained individual funding
to meet the needs of that site’s study. Sites have shared resources including study protocols and consents to
decrease costs and improve study flow. This PMA protocol is registered with the Cochrane Collaboration and data
will be analyzed according to Cochrane standards for meta-analysis.
Conclusions: PMA is a novel research method that improves meta-analysis by including several study sites,
establishing uniform reporting of specific outcomes, and yet allowing some independence on the part of
individual sites with respect to the conduct of research. The inclusion of several sites increases statistical power
to address important clinical questions. Compared to multi-center trials, PMA methodology encourages
collaboration, aids in the development of new investigators, decreases study costs, and decreases time to
publication.
Trial Registration: ClinicalTrials.gov: NCT00613366, NCT00886834, NCT01001897, NCT01147497 and NCT01307111
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Introduction
While well-conducted multi-center randomized con-
trolled trials (RCTs) and meta-analyses are the gold stan-
dard for evidenced based medicine, they have
weaknesses. Multi-center trials, managed by a single
institution, require uniform IRB submission and study
procedures from all participating institutions. Multi-cen-
ter trials are expensive and give little flexibility to indivi-
dual sites. Meta-analysis has become a common research
tool to combine data from several trials and analyze them
in the aggregate. However, traditional meta-analysis often
suffers from the heterogeneity of included trials where
each individual study may have tested a unique interven-
tion and assessed a unique primary outcome. Other pit-
falls associated with meta-analyses when trying to
include all relevant data include selective reporting biases
and unwillingness by researchers to share their data.
Prospective meta-analysis (PMA) is a collaborative
research design in which individual sites perform rando-
mized controlled trials (RCTs) and then contribute their
data to the collaboration for the meta-analysis. The main
a d v a n t a g eo fP M Ai st h eu n i f o r m i t yo ft h ei n t e r v e n t i o n
(e.g. drug dosing) and data collection instruments for the
primary and secondary outcomes. Additional advantages
of the PMA methodology include the ability for indivi-
dual sites to recruit only the required number of subjects
for a site-specific primary outcome (in this case such as
pain with IUD insertion or ease of IUD insertion) and to
maintain autonomy over this smaller project. Combining
results from each institution creates the power necessary
to answer research questions requiring a larger number
of subjects than many institutions could recruit individu-
ally. For example, only two sites are powered for the pri-
mary PMA outcome in our study.
PMAs allow flexibility at individual sites to maximize
participant recruitment and the participation of sites
with smaller research programs to contribute to a larger
statistically powerful study. Additionally, PMA metho-
dology promotes mentoring, and minimizes costs. Data
are pooled with retention of stratification by study site
and analyzed by the collaboration to determine the
PMA primary outcome, while each site may analyze and
publish its own data. Our project utilizes PMA metho-
dology to assess whether misoprostol reduces the need
for adjunctive measures to insert an intrauterine device
(IUD) in nulliparous women. We aim to introduce this
promising research methodology within the family plan-
ning research community.
PMA as a Research Tool
Meta-analysis increases statistical power and provides
more precise estimates of treatment effect by increasing
sample size. While meta-analysis has become common
in the medical literature, prospective meta-analysis is a
relatively new methodology. In PMA, the specific inter-
ventions as well as the primary and secondary outcomes
are determined before data from specific trials are pub-
lished. In some PMAs, the research collaboration occurs
before initiation of any study procedures. In this ideal
model, co-investigators discuss study questions, study
outcomes and study procedures prior to initiation of
any of the site studies. In other PMAs, investigators
have begun a study but determine they need more sub-
jects than available at their site/s. In this case, prior to
the completion of subject enrollment, they may create a
PMA, inviting other investigators to collaborate with
individual RCTs, but with some uniformity in study out-
comes and procedures. In all cases, the PMA protocol
must be finalized prior to the publication of results by
any individual trial.
Once the research plan is developed and agreed upon
by collaboration, each contributing site conducts its own
RCT. The de-identified data, ideally including individual
patient data, are pooled to perform the meta-analysis.
PMA has been championed by experts in scientific evi-
dence [1,2], and a study section of the Cochrane Colla-
boration is dedicated to this methodology [3]. PMA has
been employed to address a variety of research ques-
tions, including reduction of cholesterol [4], treatment
of hypertension [5], reduction of functional declines in
elderly hospitalized patients [6,7], the role of genetics in
disease outcomes [8,9], neonatal effects of epidural
anesthesia [10], and childhood acute lymphoblastic leu-
kemia [11]. The research effort described in this paper
is the first to be registered with the Cochrane Collabora-
tion [12].
A PMA Example: Cholesterol Trials and Mortality
The PMA process is illustrated with the following exam-
ple. Several large-scale trials were in progress to assess
the impact of various statins (HMG-CoA reductase inhi-
bitors) on a variety of cardiovascular outcomes. None of
these trials was powered independently to assess cardio-
vascular and non-cardiovascular mortality [13]. The
investigators of these studies agreed to contribute to a
PMA addressing mortality. Included trials were required
to utilize proper randomization procedures, to assign
lipid modification as the main study variable, and to
enroll at least 1000 patients for at least 2 years of fol-
low-up. Data from 14 trials were combined resulting in
90,056 patients with a mean follow up of 5 years. The
PMA demonstrated statistically powerful reductions in
both all-cause and coronary mortality [9]. PMA
answered an important clinical question that no indivi-
dual center or trial could have resolved. This was
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address secondary outcomes than a traditional meta-
analysis for less cost and with greater investigator auton-
omy than a multi-center RCT. PMA may also be used
for outcomes requiring smaller numbers of subjects
with equal effectiveness [10].
Advantages of PMA
Because all sites contributing to a PMA must agree on
the intervention and the measurement of the primary
and secondary outcomes, a primary flaw of conventional
meta-analyses, the disparity across trials on interven-
tions and measurement of outcomes, is avoided. With-
out the collaborative decisions of the PMA, independent
sites could potentially generate incompatible data, mak-
ing meta-analysis difficult and decreasing the statistical
power of the primary outcom e .I nP M A ,a n a l y s i so f
pooled results is more facile because of homogeneity of
study outcome measures. A detailed description of this
group’s PMA protocol and data analysis plan is available
in the Cochrane protocol document [14]. In addition,
when individual patient data are available for all studies
included in a meta-analysis, as occurs in a PMA,
researchers have the ability to conduct stratified analyses
and to control for potentially confounding variables.
After agreeing upon critical aspects of protocols by
those contributing to the collaboration, the PMA pro-
cess benefits from its otherwise decentralized nature.
PMA, because of its decentralization, requires fewer
resources than a multi-center RCT. When sites conduct
their own trials, they may develop protocols that best fit
their site and interests, including the availability of study
participants, the development of unique secondary out-
comes, the availability of institutional resources and the
requirements of the site’s institutional review board
(IRB). Time to completion of a PMA site’s study may be
expedited by avoiding the individual site IRB difficulties
that often occur in multi-center trials with centralized
study protocols. Individual sites may begin recruiting
participants and collecting study data once they have
obtained IRB approval without waiting for approval
from all sites. Data collection does not have to occur
concurrently at all sites.
Decentralization encourages study population diversity
improving the external validity of study results. Decen-
tralization also lowers costs by avoiding centralized
oversight. While economies of scale in a multi-center
trial can be cost-effective in relation to placebo manu-
facture and printed materials, these savings may be
quickly offset by the expense of site visits. Co-investiga-
tors can pursue smaller grants for individual sites rather
than a pursuing a large, less readily obtainable grant for
an unwieldy and costly multi-center trial. Internal
validity is maintained since each site publishes the
results of its own trial.
The PMA allows significant flexibility in trial design at
individual sites. Other than the primary outcome, sec-
ondary outcomes and eligibility criteria agreed upon by
the 6 sites, each site was free to design a trial that was
different in some way. For example, although there is
general agreement with the misoprostol dosing regimen
of 400 mcg within the family planning community
based on pharmacokinetic data [15,16], decisions about
route of administration and timing of dosing were left
to the individual sites. As a result of this design free-
dom, one site is testing at home vaginal or buccal
administration of misoprostol 3 to 4 hours prior to
insertion while a different site is using administration 90
minutes prior to insertion. The group of collaborators
had two in-person meetings and many email communi-
cations before all members of the collaborative group
agreed on the final PMA protocol.
PMA methodology also allows several investigators
from each site to conduct the study and to qualify for
authorship of individual site publications. In contrast, in
multi-center RCTs, authorship is commonly limited to
the principal investigators at each site. In PMA, indivi-
dual publications focusing on unique secondary out-
comes further knowledge in the field. Given publication
requirements for promotion at academic institutions,
PMA offers the advantage of expanding opportunities
for research participation and authorship of peer-
reviewed publications. The responsibility of authorship
may optimize individual site study protocol execution (e.
g. proper administration of medications, maximizing
participant retention, collecting all data points) and
motivate individual sites to conclude the project in a
timely fashion.
PMAs may include both experienced researchers and
new investigators with a shared research interest. Since
individual PMA study sites may include a number of
researchers, the spectrum of novice to experienced
researcher may play a role and become study authors.
Multi-center trials commonly utilize the most experi-
enced research institutions with the greatest patient
volumes, making it difficult for smaller sites with a less
established research infrastructure to participate. By
including both senior and new researchers, the PMA
provides a vehicle for mentorship and enables multiple
sites the opportunity to gain research experience and
expertise. Participation in PMA provides smaller sites
and less experienced researchers with well-developed
protocols and the opportunity to recruit smaller num-
bers of participants. Broader use of PMA may encourage
the family planning community to increase research
capacity through collaboration.
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insertion in nulliparous women
IUDs are an ideal method of contraception for many
women as they are effective, have few side effects or
contraindications, require only a single act of motivation
for many years of use and are highly rated among users
[17,18]. While there is broad support for IUD use in
nulliparous women [18-21], the actual insertion may be
more difficult in nulliparous than in parous women.
Several adjunct measures have been employed by health-
care providers to ease pain associated with IUD inser-
tion [22]. Although misoprostol is commonly used to
dilate the cervix for procedures similar to IUD insertion
such as in first trimester abortion [23,24], hysteroscopy
[25,26] and endometrial biopsy [27], there is a paucity
of data regarding misoprostol use by providers to ease
IUD insertion in nulliparous women [28,29].
The need for more definitive data to determine the
efficacy of misoprostol use to ease IUD insertion in nul-
liparous women prompted the design of our PMA. Spe-
cifically, we wished to assess whether or not cervical
preparation with misoprostol in nulliparous women
affects the need for adjunctive measures for IUD inser-
tion, such as use of ultrasound guidance, cervical dila-
tion, anesthesia and/or analgesia. This research question
is particularly amenable to PMA methodology because
the outcome-difficulty with IUD insertion in nulliparous
women-is relatively uncommon, requiring a large sample
size.
Methods
A preliminary PMA protocol was developed by an inves-
tigator and was submitted for review to the Prospective
Meta-Analysis Methods Group of the Cochrane Colla-
boration. While the protocol was under review, potential
collaborating sites were identified through a search of
clinicaltrials.gov, by contacting known family planning
researchers, and by presenting the PMA design and
study plan at a national meeting of contraceptive
researchers (Reproductive Health 2008, Minneapolis,
MN). Only investigators able to enroll subjects to meet
a pre-determined sample size joined the PMA group.
The group of PMA co-investigators was formed to make
collective decisions about a common protocol and to
determine site responsibilities. Included in the group
were a representative from each site, an epidemiologist
(SS), and an expert in meta-analysis (KS). The project is
coordinated through the University of Utah where the
principal investigator conducts research. The contribu-
tors have an authorship agreement for final publication
based on recruitment numbers.
Each site modified a template to create a unique pro-
tocol and independently coordinates its site’ss t u d y ,
using its institutional IRB. De-identified data from each
site will be included in the PMA database, assuming
subjects are properly randomized, the same interven-
tions are examined, and outcome data on primary and
secondary endpoints are included. Each individual trial
is registered on clinicaltrials.gov, follows CONSORT
guidelines [30] and will be published independently. If
other sites not currently participating in this collabora-
tion meet the above criteria and have not published
results, they will be invited to join the PMA. If possible,
t h eP M Aw i l lr e v i e ws t u d yp r o t o c o l sp r i o rt o
implementation.
Prior to initiating the PMA, we searched computerized
databases to assure that no published studies already
met the requirements of this PMA. We searched for
ongoing trials on the WHO International Clinical Trials
Registry Platform (ICTRP) - http://apps.who.int/trial-
search/; National Institutes of Health (NIH) - rando-
mized trial records (ClinicalTrials.gov); as well as the
metaRegister of Controlled Trials - http://controlled-
trials.com/mrct. With no date or language restrictions,
we searched for published trials on PubMed, the
Cochrane Central Register of Controlled Trials (CEN-
TRAL), POPLINE, and EMBASE. We searched reference
lists of retrieved titles for previously unidentified studies
and attempted to identify unpublished trials by contact-
ing experienced family planning researchers. In addition,
we annually review the proceedings of conferences with
a focus on contraception to become aware of any
ongoing or future trials on the subject.
The primary outcomes of our PMA are: 1) To com-
pare the ability to insert IUDs without the use of
adjunctive methods (use of ultrasound guidance, cervical
dilation, placement of a paracervical block and/or use of
additional pain medication) in nulliparous women who
were randomly assigned to misoprostol 400 mcg or pla-
cebo by any route of administration within 24 hours of
IUD insertion, 2) to compare pain scores between the
two groups using a 100-mm validated visual analogue
scale, and 3) to compare providers’ rating of ease of
insertion using a 100-mm validated visual analogue
scale. The sample size necessary to detect a difference
between a 10% need for adjunctive measures for IUD
insertion in the placebo group and 2% need in the miso-
prostol group is 208 patients in each group assuming a
1:1 ratio of treatment assignment, a = 0.05, b =0 . 1 0
with 90% power. This would require 416 patients total.
Upon completion of the study at each site, individual
patient data will contribute to the final meta-analysis
using criteria outlined in the Cochrane Handbook for
Systematic Reviews of Interventions [31]. Individual trial
sites are encouraged to mention in publication of their
individual results that their data are being contributed
to this PMA. The coordinating site for the PMA final
analysis is the University of Utah as agreed upon when
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Protocol document [14]. In addition, specific subgroup
analyses are delineated in the Cochrane Protocol docu-
ment and include timing of insertion relative to menses,
type of IUD inserted, and variations in misoprostol tim-
ing and administration [14].
Results
Six sites were identified and agreed to collaborate on
t h eP M A .T h es t u d ys i t e s ,t h e ir representative to the
collaboration, target recruitment goals, and primary
outcome to be assessed at that site are listed in Table
1. Three in-person meetings with attendees from all
sites have been held over two years as well as a num-
ber of electronic communications. Through this pro-
cess a PMA protocol and database were created and
agreed upon by all 6 sites. Sites have benefitted from
the use of shared resources: the study protocol, con-
sent forms, data collection sheets, and study database
have been shared between sites. Each site has modified
the documents as needed to conduct its individual
trial. Sharing of resources reduces the time commit-
ment of co-investigators and ensures uniform data col-
lection and entry for primary and secondary outcomes
of the PMA. In addition, a central pharmacy is used by
several sites to produce the randomized sequences of
misoprostol and placebo pills, which are identical in
appearance, taste, and odor. Especially important in a
meta-analysis that relies on individual patient data, the
use of a similar database for all sites will save consid-
erable effort in determining the final results of the
PMA.
All six sites have IRB approval for this project. As of
April 22, 2011, three sites have completed enrollment
and are at various stages of reporting results. The
remaining three sites have begun enrollment and are
proceeding with data collection. Individual sites have
registered their trials at the National Institutes of Health
Clinical Trials Registry (ClinicalTrials.gov identifiers#
NCT00613366, NCT00886834, NCT01001897,
NCT01147497 and NCT01307111). The final PMA will
be published in the Cochrane Collaboration.
Discussion
The adoption of PMA methodology by the family plan-
ning community may assist in answering research ques-
tions that require a larger sample size while avoiding
some of the limitations of a traditional meta-analysis.
PMA provides mentorship to new investigators and
gives multiple sites, including those with less research
infrastructure, the opportunity to participate in a trial.
Broader use of PMA has the potential to promote more
rapid and effective growth of the Family Planning
research community, encouraging the testing of more
hypotheses in well-designed clinical trials.
A primary aim of our PMA is to create a network that
will foster novel research programs, particularly at sites
with less research experience. While some sites are
more likely to fulfill their enrollment projections, a site
falling short of its goal will not derail the overall process
and can still contribute the data that were collected to
the PMA. The PMA can still reach the overall target
number of subjects by enrolling additional participants
at other sites. By identifying the outcomes of interest
prior to individual study design, the PMA allows genera-
t i o no ft h es a m es p e c i f i cm easured endpoints from the
study sites. Besides ease of analysis of these compatible
data sets, the PMA methodology increases statistical
power and allows smaller study sites to pool data. Flex-
ibility is integral to the PMA process.
Table 1 Collaborative Group with Site-specific Primary Outcome and Sample Size
Institution Primary
investigator
Route & timing* of
misoprostol
administration
Site-specific primary outcome Target
recruitment
Emory University
School of
Medicine
Eva Lathrop buccal 2 hours prior Ability to have the IUD inserted without the use of ancillary measures
including mechanical dilation of the cervix, placement of paracervical
nerve block, or using abdominal ultrasound for guidance.
75
Oregon Health &
Science University
Alison
Edelman
Buccal, 90 minutes Patient perceived pain on 100-mm visual analogue scale (VAS;anchors:0
= none,100 mm = worst imaginable)
40
University of
Arizona
Pamela
Lotke
Vaginal or buccal 2
hours prior
Patient perceived pain on 100-mm visual analogue scale (VAS;anchors:0
= none,100 mm = worst imaginable)
60
University of
Colorado
Stephanie
Teal
Sublingual, 2 hours prior Able to have the IUD inserted in a standard fashion without the ancillary
measures of mechanical dilation of the cervix, placement of paracervical
nerve block, or using abdominal ultrasound for guidance.
150
University of New
Mexico
Eve Espey Buccal, 2 hours prior Patient perceived pain on 100-mm visual analogue scale (VAS;anchors:0
= none,100 mm = worst imaginable)
80
University of Utah David Turok Buccal or vaginal 2-4
hours prior
Operator perceived ease of insertion (based on a 100-mm visual
analogue scale -anchors: 0 _ extremely easy, 100 mm_impossible).
100
*"timing” reflects number of minutes misoprostol will be administered prior to IUD insertion
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supported by the hosting sites. A multi-center trial
examining the same outcomes would have required
much greater funding which typically requires consider-
able time to obtain. The small amount of funding for
our PMA may ultimately yield a significant impact in a
shorter time frame.
A benefit of registering a PMA with the Cochrane
Collaboration is the review of the PMA protocol by
some of the world’s most experienced clinical trial
researchers. For studies in the family planning field, this
review is conducted by the Fertility Regulation Group of
the Cochrane Collaboration http://www.fertility-regula-
tion.org/. Continued use of the Cochrane Collaborative
for this function will improve Family Planning research
and place our research community in the vanguard of
evidenced-based medicine.
Conclusions
The six sites involved in our PMA collaboration have
employed this research method to answer an important
patient care question while improving research commu-
nity cooperation and maintaining site autonomy. The
process of developing this PMA has strengthened the col-
laborating research sites by fostering protocol develop-
ment, reducing costs, aiding new investigators, and
increasing statistical power to address the use of miso-
prostol prior to IUD insertion in nulliparous women.
Answering a question of such broad importance to U.S.
women will be the significant result of several sites’ parti-
cipation in the PMA. Future use of PMA methodology in
the Family Planning research community could be help-
ful in addressing other important research questions
such as the ideal technique for postpartum IUD insertion,
cervical preparation for second trimester abortion, and
approaches to improve the uptake of highly effective long
acting methods of contraception. Having gained familiar-
ity with PMA design, development and execution, this
collaborative group is uniquely poised to expand the use
of PMA to address these important research questions.
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